Seminars in Oncology
Volume 33 , Pages 26-32 , February 2006

Clinical Experience: Practical Management of Five Patients With Cutaneous T-Cell Lymphoma (CTCL)-Related Symptoms

  • Reinhard Dummer

      Affiliations

    • University Hospital of Zurich, Switzerland
    • Corresponding Author InformationAddress correspondence and reprint requests to Reinhard Dummer, MD, Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland
    • ,
  • Francine Foss

      Affiliations

    • Yale Center, New Haven, CT
    • ,
  • Brigitte Dreno

      Affiliations

    • Unit of Skin Oncology, Nantes, France
    • ,
  • Martine Bagot

      Affiliations

    • Paris 12 University, Paris, France

References 

  1. Dummer R , Kempf W , Hess Schmid M , et al.   Therapy of cutaneous lymphoma-current practice and future developments . Onkologie . 2003;26:366–372
  2. Stadler R , Otte HG , Luger T , et al.   Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II . Blood . 1998;92:3578–3581
  3. Maier T , Tun Kyi A , Tassis A , et al.   Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells . Blood . 2003;102:2338–2344
  4. Dummer R , Hassel JC , Fellenberg F , et al.   Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas . Blood . 2004;104:1631–1638
  5. Duvic M , Hymes K , Heald P , et al.   Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma (Multinational phase II-III trial results) . J Clin Oncol . 2001;19:2456–2471
  6. Singh F , Lebwohl MG . Cutaneous T-cell lymphoma treatment using bexarotene and PUVA (A case series) . J Am Acad Dermatol . 2004;51:570–573
  7. Michaelis S , Cozzio A , Kempf W , et al.   Combination of bexarotene and psoralen-UVA therapy in a patient with Mycosis fungoides . Dermatology . 2004;209:72–74
  8. Gorgun G , Foss F . Immunomodulatory effects of RXR rexinoids (Modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox) . Blood . 2002;100:1399–1403
  9. Porcu P, Baiocchi R, Buckner M, et al: Bexarotene-induced T-cell immunomodulation an response in CTCL. Blood 104:744, 2004 (abstr)
  10. Bagot M , Moretta A , Sivori S , et al.   CD4+ cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor . Blood . 2001;97:1388–1391
  11. Gottlieb SL , Wolfe JT , Fox FE , et al.   Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa (A 10-year experience at a single institution) . J Am Acad Dermatol . 1996;35:946–957
  12. Duvic M , Hymes K , Heald P , et al.  Bexarotene Worldwide Study Group   Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma (Multinational phase II-III trial results) . J Clin Oncol . 2001;19:2456–2471
  13. Wollina U , Graefe T , Kaatz M . Pegylated doxorubicin for primary cutaneous T cell lymphoma (A report on ten patients with follow-up) . Ann N Y Acad Sci . 2001;941:214–216
  14. Coors EA , von den Driesch P . Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy . Br J Dermatol . 2000;143:127–131
  15. Zackheim HS , Epstein EH . Low-dose methotrexate for the Sezary syndrome . J Am Acad Dermatol . 1989;21:757–762
  16. Dummer R , Willers J , Kamarashev J , et al.   Pathogenesis of cutaneous lymphomas . Semin Cutan Med Surg . 2000;19:78–86
  17. Karenko L , Hyytinen E , Sarna S , et al.   Chromosomal abnormalities in cutaneous T-cell lymphoma and in premalignant conditions as detected by G-banding and interphase cytogenetic methods . J Invest Dermatol . 1997;108:22–29
  18. Kaye FJ , Bunn PJ , Steinberg SM , et al.   A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides . N Engl J Med . 1989;321:1784–1790
  19. Dummer R . Emerging drugs in cutaneous T-cell lymphomas . Expert Opin Emerg Drugs . 2005;10:381–392
  20. Weinstock MA , Gardstein B . Twenty year trends in the reported incidence of mycosis fungoides and associated mortality . Am J Public Health . 1999;89:1240–1244
  21. Office for National Statistics, Cancer Statistics Registrations. Registrations of Cancer Diagnosed in 2000, England. Series MB1, No 31
  22. Child FJ , Mitchell TJ , Whittaker SJ , et al.   A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides . Clin Exp Dermatol . 2004;29:231–236
  23. Whittaker SJ , Marsden JR , Spittle M , et al.   Joint British Association of Dermatologists and U.K . Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol . 2003;149:1095–1107

 This supplement was supported by an unrestricted educational grant from Zeneus Pharma Ltd.

 Prof Foss is a member of the speakers’ bureau for Ligand Pharmaceuticals. Prof Bagot has served as a consultant to Zeneus. Prof Dummer has participated in scientific symposia and advisory boards sponsored by Zeneus and Ligand Pharmaceuticals.

PII: S0093-7754(05)00514-2

doi: 10.1053/j.seminoncol.2005.12.020

Seminars in Oncology
Volume 33 , Pages 26-32 , February 2006

Article Tools

* Image Usage & Resolution